Artelo Biosciences reports positive interim Phase 2 data for ART27.13 in cancer cachexia; seeks licensing partner

ARTELO BIOSCIENCES, INC.

Interim Phase 2 CAReS: ART27.13 patients gained 6.38% mean body weight vs placebo loss of -5.42% at 12 weeks.
Lean body mass increased +4.23% in treatment group vs -3.15% loss in placebo at one month.
Safety: 22% of 32 patients had possibly related adverse events, all mild/moderate except one severe malaise; no drug-related serious AEs.
Company will not internally fund Phase 3; plans to pursue licensing/partnership for ART27.13 as most value-accretive path.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.